Granulocyte macrophage-colony-stimulating factor autoantibodies and increased intestinal permeability in crohn disease

Journal of Pediatric Gastroenterology and Nutrition

Volumn 52, Issue 5, 2011, Pages 542-548

  Nylund, Cade M ^a,d   D'Mello, Sharon ^a   Kim, Mi Ok ^a   Bonkowski, Erin ^a   Däbritz, Jan ^b   Foell, Dirk ^b   Meddings, Jon ^c   Trapnell, Bruce C ^a   Denson, Lee A ^a  

^a UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF MÜNSTER   (Germany)

^c UNIVERSITY OF ALBERTA   (Canada)

^d UNIFORMED SERVICES UNIVERSITY OF THE HEALTH SCIENCES   (United States)

Author keywords

Bowel permeability; Crohn disease; granulocyte macrophagecolony stimulating factor antibodies; sargramostim

Indexed keywords

ANTIBIOTIC AGENT; AUTOANTIBODY; BIOLOGICAL MARKER; CASPASE RECRUITMENT DOMAIN PROTEIN 15; CORTICOSTEROID; ENDOTOXIN; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR ANTIBODY; IMMUNOMODULATING AGENT; INFLIXIMAB; LACTULOSE; LIPOPOLYSACCHARIDE BINDING PROTEIN; MANNITOL; MESALAZINE; PROTEIN S100A12; UNCLASSIFIED DRUG;

ADULT; ANTIBODY BLOOD LEVEL; ARTICLE; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; CROHN DISEASE; DISEASE ACTIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FECES LEVEL; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; INFLAMMATION; INTESTINE MUCOSA PERMEABILITY; MALE; PRIORITY JOURNAL; SCHOOL CHILD; URINARY EXCRETION;

ACUTE-PHASE PROTEINS; ADOLESCENT; AUTOANTIBODIES; CARRIER PROTEINS; CASE-CONTROL STUDIES; CHILD; CROHN DISEASE; FEMALE; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HUMANS; INFLAMMATION; INTESTINAL ABSORPTION; INTESTINAL MUCOSA; INTESTINES; LACTULOSE; MALE; MANNITOL; MEMBRANE GLYCOPROTEINS; PERMEABILITY; S100 PROTEINS;

MUS;

EID: 79955562015     PISSN: 02772116     EISSN: None     Source Type: Journal    
DOI: 10.1097/MPG.0b013e3181fe2d93     Document Type: Article

References (42)

1. Bernstein CN, Wajda A, Svenson LW, et al. The epidemiology of inflammatory bowel disease in Canada: a population-based study. Am J Gastroenterol 2006;101:1559-68. (Pubitemid 43980630)
2. Kugathasan S, Judd RH, Hoffmann RG, et al. Epidemiologic and clinical characteristics of children with newly diagnosed inflammatory bowel disease in Wisconsin: a statewide population-based study. J Pediatr 2003;143:525-31. (Pubitemid 37352514)
3. Vind I, Riis L, Jess T, et al. Increasing incidences of inflammatory bowel disease and decreasing surgery rates in Copenhagen City and County, 2003-2005: a population-based study from the Danish Crohn Colitis Database. Am J Gastroenterol 2006;101:1274-82. (Pubitemid 43833122)
4. Hanauer SB. Inflammatory bowel disease: epidemiology, pathogenesis, and therapeutic opportunities. Inflamm Bowel Dis 2006;12(suppl 1): S3-9. (Pubitemid 43068428)
5. Dubinsky MC, Taylor K, Targan SR, et al. Immunogenetic phenotypes in inflammatory bowel disease. World J Gastroenterol 2006;12:3645-50. (Pubitemid 43950940)
6. Valentine JF, Fedorak RN, Feagan B, et al. Steroid-sparing properties of sargramostim in patients with corticosteroid-dependent Crohn' disease: a randomised, double-blind, placebo-controlled, phase 2 study. Gut 2009;58:1354-62.
7. Takazoe M, Matsui T, Motoya S, et al. Sargramostim in patients with Crohn's disease: results of a phase 1-2 study. J Gastroenterol 2009; 44:535-43.
8. Dieckgraefe BK, Korzenik JR. Treatment of active Crohn's disease with recombinant human granulocyte-macrophage colony-stimulating factor. Lancet 2002;360:1478-80. (Pubitemid 35356328)
9. Korzenik JR, Dieckgraefe BK, Valentine JF, et al. Sargramostim for active Crohn's disease. N Engl J Med 2005;352:2193-201.
10. Marks DJ, Harbord MW, MacAllister R, et al. Defective acute inflammation in Crohn's disease: a clinical investigation. Lancet 2006;367: 668-78. (Pubitemid 43289157)
11. Kobayashi KS, Chamaillard M, Ogura Y, et al. Nod2-dependent regulation of innate and adaptive immunity in the intestinal tract. Science 2005;307:731-4. (Pubitemid 40194644)
12. Kramer M, Netea MG, de Jong DJ, et al. Impaired dendritic cell function in Crohn's disease patients with NOD2 3020insC mutation. J Leukoc Biol 2006;79:860-6. (Pubitemid 44835619)
13. Yamamoto-Furusho JK, Korzenik JR. Crohn's disease: innate immunodeficiency? World J Gastroenterol 2006;12:6751-5.
14. Comalada M, Peppelenbosch MP. Impaired innate immunity in Crohn's disease. Trends Mol Med 2006;12:397-9. (Pubitemid 44291569)
15. Shibata Y, Berclaz PY, Chroneos ZC, et al. GM-CSF regulates alveolar macrophage differentiation and innate immunity in the lung through PU.1. Immunity 2001;15:557-67. (Pubitemid 33016441)
16. Uchida K, Beck DC, Yamamoto T, et al. GM-CSF autoantibodies and neutrophil dysfunction in pulmonary alveolar proteinosis. N Engl J Med 2007;356:567-79. (Pubitemid 46220817)
17. Han X, Uchida K, Jurickova I, et al. Granulocyte-macrophage colony-stimulating factor autoantibodies in murine ileitis and progressive ileal Crohn's disease. Gastroenterology 2009;136: 1261-71. e1-e3.
18. May GR, Sutherland LR, Meddings JB. Is small intestinal permeability really increased in relatives of patients with Crohn's disease? Gastroenterology 1993;104:1627-32. (Pubitemid 23235451)
19. Hollander D, Vadheim CM, Brettholz E, et al. Increased intestinal permeability in patients with Crohn's disease and their relatives. A possible etiologic factor. Ann Intern Med 1986;105:883-5. (Pubitemid 17201765)
20. D'Inca R, Annese V, di Leo V, et al. Increased intestinal permeability and NOD2 variants in familial and sporadic Crohn's disease. Aliment Pharmacol Ther 2006;23:1455-61.
21. Buhner S, Buning C, Genschel J, et al. Genetic basis for increased intestinal permeability in families with Crohn's disease: role of CARD15 3020insC mutation? Gut 2006;55:342-7. (Pubitemid 43268271)
22. Irvine EJ, Marshall JK. Increased intestinal permeability precedes the onset of Crohn's disease in a subject with familial risk. Gastroenterology 2000;119:1740-4. (Pubitemid 32198699)
23. Silverberg MS, Satsangi J, Ahmad T, et al. Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: report of a Working Party of the 2005 Montreal World Congress of Gastroenterology. Can J Gastroenterol 2005;19(suppl A):5-36.
24. Breslin NP, Nash C, Hilsden RJ, et al. Intestinal permeability is increased in a proportion of spouses of patients with Crohn's disease. Am J Gastroenterol 2001;96:2934-8. (Pubitemid 32959536)
25. Meddings JB, Sutherland LR, May GR. Intestinal permeability in patients with Crohn's disease. Gut 1994;35:1675-6. (Pubitemid 24339279)
26. Foell D, Kucharzik T, Kraft M, et al. Neutrophil derived human S100A12 (EN-RAGE) is strongly expressed during chronic active inflammatory bowel disease. Gut 2003;52:847-53. (Pubitemid 36613492)
27. Kaiser T, Langhorst J, Wittkowski H, et al. Faecal S100A12 as a noninvasive marker distinguishing inflammatory bowel disease from irritable bowel syndrome. Gut 2007;56:1706-13. (Pubitemid 350206297)
28. Teshima CW, Meddings JB. The measurement and clinical significance of intestinal permeability. Curr Gastroenterol Rep 2008;10:443-9.
29. Yacyshyn BR, Pilarski LM. Expression of CD45RO on circulating CD19+ B-cells in Crohn's disease. Gut 1993;34:1698-704. (Pubitemid 23353162)
30. Pasternak BA, D'Mello S, Jurickova II, et al. Lipopolysaccharide exposure is linked to activation of the acute phase response and growth failure in pediatric Crohn's disease and murine colitis. Inflamm Bowel Dis 2010;16:856-69.
31. Foell D, Wittkowski H, Roth J. Monitoring disease activity by stool analyses: from occult blood to molecular markers of intestinal inflammation and damage. Gut 2009;58:859-68.
32. Zweigner J, Schumann RR, Weber JR. The role of lipopolysaccharidebinding protein in modulating the innate immune response. Microbes Infect 2006;8:946-52.
33. Suenaert P, Bulteel V, Lemmens L, et al. Anti-tumor necrosis factor treatment restores the gut barrier in Crohn's disease. Am J Gastroenterol 2002;97:2000-4.
34. Suenaert P, Bulteel V, Vermeire S, et al. Hyperresponsiveness of the mucosal barrier in Crohn's disease is not tumor necrosis factor-dependent. Inflamm Bowel Dis 2005;11:667-73. (Pubitemid 40961081)
35. Harbord MW, Marks DJ, Forbes A, et al. Impaired neutrophil chemotaxis in Crohn's disease relates to reduced production of chemokines and can be augmented by granulocyte-colony stimulating factor. Aliment Pharmacol Ther 2006;24:651-60. (Pubitemid 44127847)
36. Korzenik JR, Dieckgraefe BK. Is Crohn's disease an immunodeficiency? A hypothesis suggesting possible early events in the pathogenesis of Crohn's disease. Dig Dis Sci 2000;45:1121-9. (Pubitemid 30409456)
37. Dunlop SP, Hebden J, Campbell E, et al. Abnormal intestinal permeability in subgroups of diarrhea-predominant irritable bowel syndromes. Am J Gastroenterol 2006;101:1288-94. (Pubitemid 43829995)
38. Maran AG, Small M, Ferguson A, et al. Small bowel permeability in patients with nasal polyposis. Rhinology 1986;24:195-8. (Pubitemid 16029724)
39. Bjarnason I, Takeuchi K. Intestinal permeability in the pathogenesis of NSAID-induced enteropathy. J Gastroenterol 2009;44(Suppl. 19):23-9.
40. Kerckhoffs AP, Akkermans LM, de Smet MB, et al. Intestinal permeability in irritable bowel syndrome patients: effects of NSAIDs. Dig Dis Sci 2010;55:716-23.
41. Hilsden RJ, Meddings JB, Sutherland LR. Intestinal permeability changes in response to acetylsalicylic acid in relatives of patients with Crohn's disease. Gastroenterology 1996;110:1395-403. (Pubitemid 26134070)
42. Meddings J. What role does intestinal permeability have in IBD pathogenesis? Inflamm Bowel Dis 2008;14(suppl 2):S138-9.